A study showed that the exogenous addition of miR-34 affects breast cancer cell survival after radiotherapy and suggests that anti-miR-34 may be used as a radiosensitizing agent in p53-mutant breast cancer (47). This evidence concerns the gene TP53 and breast carcinoma.